Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07136103 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants

A Phase 1 study of Healthy Volunteers, sponsored by AbbVie.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT07136103: Recruiting Phase 1 study of Healthy Volunteers, sponsored by AbbVie.

NCT07136103 is a Phase 1 study of Healthy Volunteers that is actively recruiting participants, run by AbbVie. The registered enrollment target is 40 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07136103, a Phase 1 study of Healthy Volunteers, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to evaluate the safety, tolerability, immunogenicity and pharmacokinetics (PK ) properties following a single dose of ABBV-277 in healthy adult participants.

Primary Outcome

Cmax of ABBV-277

Conditions Studied

Healthy Volunteers

Interventions

  • DRUG Placebo
  • DRUG ABBV-277

Study Locations (1)

Illinois

  • Acpru /Id# 265681 - Grayslake

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-08-19
Est. Completion 2026-05
Phase Phase 1
AbbVie

526 total trials

What NCT07136103 shows while recruiting

NCT07136103 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07136103 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT07136103 about?

NCT07136103 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants". The objective of this study is to evaluate the safety, tolerability, immunogenicity and pharmacokinetics (PK ) properties following a single dose of ABBV-277 in healthy adult participants.

What is the current status of trial NCT07136103?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-08-19. Estimated completion is 2026-05.

What conditions does trial NCT07136103 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT07136103?

The interventions under investigation include: Placebo (DRUG), ABBV-277 (DRUG).

Who is sponsoring clinical trial NCT07136103?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07136103 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07136103's enrollment target sits among peer trials

40 152nd of 283 higher than 124 of 283 other Healthy Volunteers trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07136103

Source: ClinicalTrials.gov NCT07136103, the US trial registry maintained by the National Library of Medicine. NCT07136103 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.